EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Attributing Broad-Spectrum Antibiotic Use After Pediatric Solid Organ Transplantation to Culture Evaluation, Surgical Infection, and Re

Lakshmy Arakoni, Kaitlyn Rivard, Blanca Gonzalez, Jessica Alban, Venkatraman Arakoni, Charles Foster

Antimicrobial Stewardship & Healthcare Epidemiology · 2026-08 · 6 (S1) · s5-s6

DOI: 10.1017/ash.2026.10437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 23.06.2026. Verfasst von Lakshmy Arakoni und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric solid organ transplant recipients receive broad-spectrum antibiotics. The CDC NHSN Antimicrobial Use and Resistance (AUR) Module reports days of therapy (DOT) by pediatric Standardized Antimicrobial Administration Ratio (SAAR) categories, but those unit-level summaries do not identify the contexts that drive broad-spectrum DOT. We used a procedure-anchored framework to quantify post-prophylaxis broad-spectrum exposure and attribute it to blood-culture evaluation, surgical site infection (SSI), and subsequent procedures.

Methods

We analyzed 164 pediatric transplant procedures (heart 59, liver 58, kidney 29, intestinal 8, multivisceral 10) with follow-up through postoperative day (POD) 365. Medication administration records were linked to procedures and transformed into an agent-day dataset with POD assignment. Organ-specific protocols defined a prophylaxis-window end day; post-prophylaxis analyses included antibiotic-days when POD exceeded end day. Broad-spectrum categories included Ped_SAAR_BSHO plus HighestRisk [Ped_SAAR_XDR (extensively drug-resistant) plus carbapenems]. SSI was chart-reviewed. A hierarchy assigned each post-prophylaxis broad-spectrum agent-day a primary context (culture, SSI, subsequent procedure, or residual unclassified). Antibiotic episodes (courses) used a locked gap rule (split if exposed-day gap ?3 days) and were linked to culture-days, SSIs or subsequent procedures to classify episode outcomes.

Results

Over POD 0–365, patients contributed 10,064 hospital-days and received 9,774 antibacterial DOT (971.2/1,000 hospital-days); Ped_BSHO contributed 2,529 DOT (251.3/1,000 hospital-days). Ped_BSHO rates varied by organ (DOT/1,000 hospital-days: 76.3 heart, 273.0 liver, 105.4 kidney, 355.5 intestinal, 494.2 multivisceral). Following completion of index procedure prophylaxis, broad-spectrum exposure totaled 2,379 DOT-days; HighestRisk accounted for 667 DOT-days (435 multivisceral). Primary attribution classified post-prophylaxis broad-spectrum DOT-days as unclassified (982; 41.3%) or blood-culture rule-out (979; 41.1%); SSI treatment windows contributed 215 DOT-days (9.0%), and subsequent procedures contributed 66 DOT-days (2.8%). Unclassified DOT was concentrated (top 10 patients 64.8%) and occurred largely in intensive care units; piperacillin–tazobactam and meropenem predominated, and 24.5% of unclassified DOT-days were HighestRisk. From 1,390 blood culture accessions we defined 1119 sets, of which 94.7% (n=1060) were no growth, 3.4% (n=38) positive and 0.5% (n=6) contaminant. In the episode-based analysis, antibiotic courses that overlapped a blood-culture day were usually rule-out rather than culture-confirmed, and rule-out episodes contributed substantially more antibiotic burden than culture-positive episodes (DOT 1,510 vs 248). Culture intensity was high in multivisceral/intestinal PICU patients and PCICU heart patients.

Conclusions

After prophylaxis ends, broad-spectrum exposure is dominated by evaluation-driven care and a large residual unclassified burden, while SSI-associated exposure remains a smaller, safety-anchored signal. This procedure-anchored, episode-based framework quantifies organ-specific burden and prioritizes targets for paired diagnostic and antibiotic stewardship.

Zitieren

APA

Arakoni, L., Rivard, K., Gonzalez, B., Alban, J., Arakoni, V., & Foster, C. (2026). Attributing Broad-Spectrum Antibiotic Use After Pediatric Solid Organ Transplantation to Culture Evaluation, Surgical Infection, and Re. Antimicrobial Stewardship & Healthcare Epidemiology, 6(S1), s5-s6. https://doi.org/10.1017/ash.2026.10437

Vancouver

Arakoni L, Rivard K, Gonzalez B, Alban J, Arakoni V, Foster C. Attributing Broad-Spectrum Antibiotic Use After Pediatric Solid Organ Transplantation to Culture Evaluation, Surgical Infection, and Re. Antimicrobial Stewardship & Healthcare Epidemiology. 2026;6(S1):s5-s6. doi:10.1017/ash.2026.10437

BibTeX
@article{Arakoni2026,
  author = {Arakoni, Lakshmy and Rivard, Kaitlyn and Gonzalez, Blanca and Alban, Jessica and Arakoni, Venkatraman and Foster, Charles},
  title = {Attributing Broad-Spectrum Antibiotic Use After Pediatric Solid Organ Transplantation to Culture Evaluation, Surgical Infection, and Re},
  journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
  year = {2026},
  volume = {6},
  number = {S1},
  pages = {s5--s6},
  doi = {10.1017/ash.2026.10437}
}
Kostenlos starten →